Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 206-213

  Garnacho Montero, José ^a,b   Díaz Martín, Ana ^a,b   García Cabrera, Emilio ^a,b   de Pipaón, Maite Ruiz Pérez ^a,b   Hernández Caballero, Clara ^a,b   Lepe Jimánez, José A ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

BSIs; Candidaemia; Prognostic factors

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CLINICAL ASSESSMENT; COMORBIDITY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FUNGUS CULTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; NEUTROPENIA; ORGAN TRANSPLANTATION; PARENTERAL NUTRITION; PROGNOSIS; SEPTIC SHOCK;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CATHETER-RELATED INFECTIONS; COHORT STUDIES; DEVICE REMOVAL; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84871203700     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks347     Document Type: Article

References (32)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Lundberg JS, Perl TM, Wiblin T et al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med 1998; 26: 1020-4.
3. Liu CY, Huang LJ, Wang WS et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 2009; 58: 154-60.
4. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 788-93.
5. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
6. Almirante B, Rodríguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
7. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
8. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
9. Parkins MD, Sabuda DM, Elsayed S et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613-8.
10. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-31.
11. Colombo AL, Guimaräes T, Silva LRBF et al. Prospective observational study of candidemia in Säo Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 2007; 28: 570-6.
12. Marriott DJE, Playford EG, Chen S et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13: R115.
13. Kludze-Forson M, Eschenauer GA, Kubin CJ et al. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 2010; 48: 436-9.
14. Grim SA, Berger K, Teng C et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012; 67: 707-14.
15. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
16. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
17. National Committee for Clinical Laboratory Standards. Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Guideline M44-A. NCCLS, Wayne, PA, USA, 2004.
18. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
19. Limper AH, Knox KS, Sarosi GA et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183: 96-128.
20. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
21. Kuse E-R, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
22. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
23. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34: 591-9.
24. Horn DL, Ostrosky-Zeichner L, Morris MI et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 2010; 29: 223-9.
25. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 1110-22.
26. Labelle AJ, Micek ST, Roubinian N et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-72.
27. Takakura S, Fujihara N, Saito T et al. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004; 23: 380-8.
28. Asmundsdoóttir LR, Erlendsdóttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study inIceland. ScandJ InfectDis 2005;37: 111-20.
29. Raad I, Hanna H, Boktour M et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38: 1119-27.
30. Montravers P, Mira J-P, Gangneux J-P et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 2011; 17: 1061-7.
31. Cohen Y, Karoubi P, Adrie C et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med 2010; 38: 826-30.
32. Kollef M, Micek S, Hampton N et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54: 1739-46.